Prof. Dr. Jean Rommelaere
Phone: +49 6221 424961




Using and training viruses...


to attack cancers.

Division of Tumor Virology


Our group/department has:

  • Demonstrated that rat and human glioma cells are targets for the oncosuppressive activity of parvovirus H-1 PV in preclinical models, irrespective of the mode of virus administration (Geletneky et al. Neuro-Oncol  2010)
  • Contributed to the launching and follow-up of the first cancer virotherapy clinical trial in Germany, i.e. a phase I/IIa study of parvovirus H-1PV in patients with glioblastoma multiforme at the Neurosurgery Dpt. of Heidelberg University Hospital (Geletneky et al. BioMed Central Cancer 2012)
  • Unraveled steps in the parvoviral life-cycle, which control virus oncolytic and spreading activities (Bär et al. PLoS Pathogens  2013)
  • Developed second generation parvovirus-based therapeutics which are significantly improved as regards the tumor target spectrum and effective virus dose (Li et al. EMBO Mol Med  2013)
  • Identified  a new AAV-encoded protein (AAP) which targets capsid proteins to the nucleolus where capsid assembly takes place – a process whose understanding is essential to the development of AAV as a gene transfer vector system (Sonntag et al. Proc Natl Acad Sci USA 2010)

2010 – 2013

  • Geletneky K, Kiprianova I, Ayache A, Koch R, Herrero Y Calle M, Deleu L, Sommer C, Thomas N, Rommelaere J and Schlehofer JR. Regression of advanced rat and human gliomas by local or systemic treatment with oncolytic  parvovirus H-1 in rat models. Neuro-Oncology 2010; 12: 804-814.
  • Geletneky K, Huesing J, Rommelaere J, Schlehofer JR, Dahm M, Krebs O, von Knebel Doeberitz M, Huber B and Hajda J. Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol. BioMed Central Cancer 2012; 12:99, DOI: 10.1186/1471-2407-12-99.
  • Bär S, Rommelaere J and Nüesch JPF.  Vesicular transport of progeny parvovirus particles through ER and Golgi regulates maturation and cytolysis. PLOS Pathogens 2013; DOI: 10.1371/journal.ppat.1003605.
  • Li JW, Bonifati S, Hristov G, Marttila T, Valmary-Degano S, Stanzel S, Schnölzer M, Mougin C, Aprahamian M, Grekova SP, Raykov Z, Rommelaere J and Marchini A. Synergistic combination of valproic acid and oncolytic parvovirus H-1PV as a potential therapy against cervical and pancreatic carcinomas. EMBO Molecular Medicine 2013; in press.
  • Sonntag F, Schmidt K, Kleinschmidt J. A viral assembly factor promotes AAV2 capsid formation in the nucleolus. Proceedings of the National Academy of Sciences of the United States of America 2010; 107 (22):10220-10225.
  • Public: INSERM, Helmholtz Association, DFG, DKH, DAAD, INCA
  • Private: ORYX GmbH CoKG, Medigene